大腸がんスクリーニング・診断市場：製品タイプ、年齢層、最終用途別-2025-2030年の世界予測

大腸がんスクリーニング・診断市場は、2023年に152億9,000万米ドルと評価され、2024年には162億1,000万米ドルに達すると予測され、CAGR 6.28％で成長し、2030年には234億3,000万米ドルに達すると予測されています。

大腸がん検診・診断市場の範囲と定義は、効果的な治療と患者の転帰改善に不可欠な大腸がんの早期発見と診断を目的とした様々な方法と技術を包含します。この市場には、大腸内視鏡検査、便潜血検査（FOBT）、軟性S状結腸鏡検査、DNAベースの便検査のような新しい非侵襲的方法などの検査が含まれます。これらのスクリーニングおよび診断法の必要性は、特に50歳以上の人や家族歴のある人の間で、大腸がんの有病率と死亡率が高いことに起因しています。主な用途には、無症状の人の早期発見や診断された患者の疾患進行のモニタリングなどがあり、エンドユーザーは病院、診断研究所、外来患者ケアセンターなど多岐にわたる。市場は、一般市民の意識の高まり、バイオテクノロジーの進歩、予防ヘルスケアを重視する政府の支援政策などの要因によって牽引されています。AI支援画像診断や在宅検査キットなどの技術革新は急成長の機会を示しており、保険会社との連携はアクセシビリティを高めることができます。しかし市場は、侵襲的な処置に対する患者の不安、高コスト、検査精度のばらつきといった限界に直面しています。市場開拓の課題としては、規制上のハードルや新興国市場における限られたヘルスケア・インフラが挙げられます。技術革新の分野としては、費用対効果の高い低侵襲検査の開発、遺伝的洞察に基づく個別化スクリーニング・プロトコルの開発、患者モニタリングのためのデジタルヘルスツールの統合などが挙げられます。この市場の性質は競争であり、改善のためには継続的な研究開発投資が必要です。事業成長のためには、企業は戦略的パートナーシップ、検査精度の向上、ヘルスケア支出の増加が見込まれる新興市場への進出に注力すべきです。課題を克服するためには、ヘルスケア格差への対応、認知度の向上、関連コストの削減を推進し、より広範な普及を目指す必要があります。

市場力学：急速に進化する大腸がんスクリーニング・診断市場の主要市場インサイトを公開

大腸がんスクリーニング・診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の大腸がん患者の増加
  • 大腸がんの早期発見を推進する政府のイニシアティブの高まり
• 市場抑制要因
  • 大腸がんスクリーニングおよび診断に関連する高コスト
• 市場機会
  • ヘルスケア部門におけるがん診断・治療のための資金と支出の増加
  • 新しく先進的ながん診断技術の発売の増加
• 市場の課題
  • 大腸内視鏡検査後の合併症に関する懸念

ポーターのファイブフォース：大腸がんスクリーニング・診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：大腸がんスクリーニング・診断市場における外部からの影響の把握

外部マクロ環境要因は、大腸がんスクリーニング・診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析大腸がんスクリーニング・診断市場における競合情勢の把握

大腸がんスクリーニング・診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス大腸がんスクリーニング・診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、大腸がんスクリーニング・診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨大腸がんスクリーニング・診断市場における成功への道筋を描く

大腸がんスクリーニング・診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で大腸がんの症例が増加
    • 大腸がんの早期発見を促進する政府の取り組みが増加
  • 抑制要因
    • 大腸がんのスクリーニングと診断に関連する高額な費用
  • 機会
    • がんの診断と治療のためのヘルスケア分野における資金と支出の増加
    • 新たな先進的ながん診断技術の導入の増加
  • 課題
    • 大腸内視鏡検査後の合併症に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 大腸がんスクリーニング・診断市場：製品タイプ別

• 機器
• 試薬とキット

第7章 大腸がんスクリーニング・診断市場：年齢層別

• 19～65歳
• 65歳以上
• 18歳まで

第8章 大腸がんスクリーニング・診断市場：最終用途別

• 臨床検査室
• 画像診断センター
• 病院・クリニック

第9章 南北アメリカの大腸がんスクリーニング・診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の大腸がんスクリーニング・診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの大腸がんスクリーニング・診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bayer AG
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Clinical Genomics Technologies Pty Ltd.
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Exact Sciences Corp.
• F. Hoffmann-La Roche Ltd.
• Fujifilm Holdings Corporation
• GE HealthCare Technologies, Inc.
• Guardant Health
• Hologic, Inc.
• Illumina, Inc.
• KARL STORZ SE & Co. KG
• Medtronic PLC
• Merck KGaA
• Myriad Genetics, Inc.
• Novigenix SA
• Olympus Corporation
• Prenetics Global Limited
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Siemens AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET RESEARCH PROCESS
• FIGURE 2. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET DYNAMICS
• TABLE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY 19 TO 65, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ABOVE 65, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY UPTO 18 YEARS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 30. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 45. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 47. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 50. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 100. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 102. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. POLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 114. POLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. QATAR COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 117. QATAR COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

The Colorectal Cancer Screening & Diagnostic Market was valued at USD 15.29 billion in 2023, expected to reach USD 16.21 billion in 2024, and is projected to grow at a CAGR of 6.28%, to USD 23.43 billion by 2030.

The scope and definition of the colorectal cancer screening and diagnostic market encompass a range of methods and technologies aimed at early detection and diagnosis of colorectal cancer, which is essential for effective treatment and improved patient outcomes. This market includes tests such as colonoscopy, fecal occult blood testing (FOBT), flexible sigmoidoscopy, and newer non-invasive methods like DNA-based stool tests. The necessity for these screening and diagnostic methods stems from the high prevalence and mortality rates associated with colorectal cancer, particularly among individuals aged 50 and older or those with a family history of the disease. Key applications include early detection in asymptomatic individuals and monitoring disease progression in diagnosed patients, with end-users spanning hospitals, diagnostic laboratories, and outpatient care centers. The market is driven by factors such as increasing public awareness, advancements in biotechnology, and supportive government policies emphasizing preventive healthcare. Technological innovations such as AI-assisted imaging and at-home testing kits represent burgeoning opportunities, while collaboration with insurance companies can enhance accessibility. However, the market faces limitations like patient apprehension towards invasive procedures, high costs, and variability in test accuracy. Market growth is challenged by regulatory hurdles and limited healthcare infrastructure in developing regions. Areas of innovation include the development of cost-effective and minimally invasive tests, personalized screening protocols based on genetic insights, and integration of digital health tools for patient monitoring. The nature of this market is competitive, with ongoing R&D investments required for improvements. For business growth, companies should focus on strategic partnerships, enhancing test accuracy, and expanding into emerging markets where increased healthcare spending is anticipated. Overcoming challenges calls for addressing healthcare disparities, promoting increased awareness, and reducing associated costs for broader adoption.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Colorectal Cancer Screening & Diagnostic Market

The Colorectal Cancer Screening & Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing cases of colorectal cancer globally
  • Rising government initiatives to promote early detection of colorectal cancer
• Market Restraints
  • High cost associated with colorectal cancer screening and diagnostic
• Market Opportunities
  • Growing funding and expenditure in the healthcare sector for cancer diagnosis and treatment
  • Increase in the launch of new and advanced cancer diagnostic technologies
• Market Challenges
  • Concerns associated with post-colonoscopy complications

Porter's Five Forces: A Strategic Tool for Navigating the Colorectal Cancer Screening & Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Colorectal Cancer Screening & Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Colorectal Cancer Screening & Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Colorectal Cancer Screening & Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Colorectal Cancer Screening & Diagnostic Market

A detailed market share analysis in the Colorectal Cancer Screening & Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Colorectal Cancer Screening & Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Colorectal Cancer Screening & Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Colorectal Cancer Screening & Diagnostic Market

A strategic analysis of the Colorectal Cancer Screening & Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Colorectal Cancer Screening & Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Clinical Genomics Technologies Pty Ltd., Eiken Chemical Co., Ltd., Epigenomics AG, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Guardant Health, Hologic, Inc., Illumina, Inc., KARL STORZ SE & Co. KG, Medtronic PLC, Merck KGaA, Myriad Genetics, Inc., Novigenix SA, Olympus Corporation, Prenetics Global Limited, QIAGEN N.V., Quest Diagnostics Incorporated, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Colorectal Cancer Screening & Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Instruments and Reagents & Kits.
• Based on Age Group, market is studied across 19 to 65, Above 65, and Upto 18 Years.
• Based on End-use, market is studied across Clinical Laboratories, Diagnostic Imaging Centers, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing cases of colorectal cancer globally
    • 5.1.1.2. Rising government initiatives to promote early detection of colorectal cancer
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with colorectal cancer screening and diagnostic
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing funding and expenditure in the healthcare sector for cancer diagnosis and treatment
    • 5.1.3.2. Increase in the launch of new and advanced cancer diagnostic technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with post-colonoscopy complications
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Colorectal Cancer Screening & Diagnostic Market, by Product Type

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents & Kits

7. Colorectal Cancer Screening & Diagnostic Market, by Age Group

• 7.1. Introduction
• 7.2. 19 to 65
• 7.3. Above 65
• 7.4. Upto 18 Years

8. Colorectal Cancer Screening & Diagnostic Market, by End-use

• 8.1. Introduction
• 8.2. Clinical Laboratories
• 8.3. Diagnostic Imaging Centers
• 8.4. Hospitals & Clinics

9. Americas Colorectal Cancer Screening & Diagnostic Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Colorectal Cancer Screening & Diagnostic Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Colorectal Cancer Screening & Diagnostic Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Bayer AG
• 4. Becton, Dickinson and Company
• 5. Bio-Rad Laboratories, Inc.
• 6. bioMerieux SA
• 7. Clinical Genomics Technologies Pty Ltd.
• 8. Eiken Chemical Co., Ltd.
• 9. Epigenomics AG
• 10. Exact Sciences Corp.
• 11. F. Hoffmann-La Roche Ltd.
• 12. Fujifilm Holdings Corporation
• 13. GE HealthCare Technologies, Inc.
• 14. Guardant Health
• 15. Hologic, Inc.
• 16. Illumina, Inc.
• 17. KARL STORZ SE & Co. KG
• 18. Medtronic PLC
• 19. Merck KGaA
• 20. Myriad Genetics, Inc.
• 21. Novigenix SA
• 22. Olympus Corporation
• 23. Prenetics Global Limited
• 24. QIAGEN N.V.
• 25. Quest Diagnostics Incorporated
• 26. Siemens AG
• 27. Sysmex Corporation
• 28. Thermo Fisher Scientific Inc.